Prostamax vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ProstamaxRecovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- SubQ, Oral
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- Daily for 10–30 days
- Once daily in rodent studies
- Key Benefits
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —